Merck's new injectable version of Keytruda walloped sales expectations.

Merck's new injectable version of Keytruda walloped sales expectations.

Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.